Composite Lymphoma

Genmab is culling a trio of early oncology assets to focus on upcoming milestones for its late-stage programs that include an ADC from its purchase of ProfoundBio. After “careful consideration,” Genmab has decided to end development of GEN1047 and GEN1056 for solid tumors, as well as GEN3017 for Hodgkin and non-Hodgkin lymphoma, CEO Jan van de Winkel said on its third-quarter earnings call Wednesday. The programs “didn’t meet the high bar we have set internally for really having a truly differentiated therapeutic candidate,” he added. GEN1047 and GEN3017 are both bispecific antibodies that Genmab was advancing by itself. GEN1056 is also an antibody asset, but is part of the company’s cancer immunotherapy pact with BioNTech that dates back to 2015. The partners initiated a Phase 1 trial in 2022. Genmab also pulled the plug on plans to start Phase 3 studies of its ADC Tivdak in previously-treated head and neck cancer. The drug won FDA accelerated approval for metastatic cervical cancer in 2021, which was converted to a full approval earlier this year. The changes mean the company will be “very focused on maximizing the potential” of its Phase 3 programs Epkinly, Rina-S, and acasunlimab, van de Winkel said. Genmab and partner AbbVie are testing Epkinly in Phase 3 trials in various B cell lymphomas. Epkinly is already approved for certain forms of diffuse large B cell lymphoma and follicular lymphoma. The CD3xCD20 bispecific reached $82 million in Q3 sales. Elsewhere, Genmab’s ADC Rina-S is in a Phase 3 trial in platinum resistant ovarian cancers after it paid $1.8 billion in April to buy ProfoundBio. At the time of the deal, van de Winkel told Endpoints News there was a “lot to digest” in terms of deciding pipeline priorities. “We need time to rank all of our internal programs versus the ProfoundBio programs,” he said. The Danish drugmaker is also advancing acasunlimab, its PD-L1x4-1BB bispecific antibody, into a Phase 3 trial for NSCLC by itself after BioNTech pulled out of a collaboration in August. Earlier in its pipeline, Genmab said it plans to share data for its Phase 2 anti-CD38 monoclonal antibody dubbed GEN3014 with partner Johnson & Johnson later this year. J&J is expected to decide whether to exercise its option for the drug in the first quarter of next year.

FORT MYERS, Fla., March 21, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is partnering with Research to Practice® for the Third Annual National General Medical Oncology Summit this week in Miami, a comprehensive educational experience designed exclusively for medical oncologists. Hundreds of physicians from across the U.S. will engage with internationally recognized cancer experts and clinical investigators who will share significant new data, promising treatment strategies and key perspectives on enhancing patient care management. Continue Reading Florida Cancer Specialists & Research Institute (FCS) is partnering with Research To Practice to host the Third Annual National General Medical Oncology Summit taking place in Miami, FL March 22-24, 2024. Several FCS leaders and physicians will serve as presenters and moderators in a vast array of multidisciplinary sessions, offering a unique perspective on cancer care from the community oncology side. "We have assembled a stellar faculty, inclusive of some of the top minds in our field for this unique event," said FCS President & Managing Physician Lucio N. Gordan, MD. "This dynamic platform supports the diverse needs of these vital clinicians who are devoted to providing their patients with the highest quality and most advanced care and treatment experience to achieve the very best outcomes." Bradley Monk, MD, FCS Director, Late-Phase Clinical Research, will serve on the faculty for a session on Gynecologic Cancers moderated by Mamta Choksi, MD, FCS medical oncologist and hematologist. The following FCS medical oncologists and hematologists will moderate didactic presentations and discussions on a variety of oncology topics: Lucio Gordan, MD, FCS President & Managing Physician – Pancreatic Cancer Gustavo Fonseca, MD, FACP, FCS Physician Director of Clinical Research – Multiple Myeloma Susmitha Apuri, MD – Prostate Cancer Sunil Gandhi, MD, FACP – Localized Breast Cancer, Localized HER2 Positive and Triple-Negative Breast Cancer, SABCS 2023 Review Shaachi Gupta, MD, MPH – Colorectal Cancer Lowell Hart, MD, FACP – Nontargeted Treatments for Lung Cancer; Metastatic Breast Cancer, Triple-Negative Breast Cancer, HER2-Positive Breast Cancer, SABCS 2023 Review Maen Hussein, MD – Renal Cell Carcinoma and Targeted Therapy for Non-Small Cell Lung Cancer Kapisthalam Kumar, MD, FACP – Gastroesophageal Cancers Zanetta Lamar, MD – Hodgkin and Non-Hodgkin Lymphoma Vikas Malhotra, MD – Urothelial Bladder Cancer Anjan Patel, MD – Hepatobiliary Cancers FCS is hosting additional opportunities for FCS physicians and clinicians to share perspectives and network with their fellow colleagues throughout the course of the weekend. "Our partnership and clinical participation in this event is consistent with our ongoing efforts to improve and enhance the delivery of cancer care in local communities across the U.S. and worldwide," said FCS Chief Executive Officer Nathan H. Walcker. Founded and led by medical oncologist Neil Love, MD, Research to Practice® has provided meaningful, relevant and unbiased educational perspectives for more than 30 years to meet the needs of oncology clinicians and positively impact the care of patients with cancer. About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com) Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with FCS participation.* Recognized for our research, FCS is a recipient of the national Clinical Trials Participation Award presented by the American Society of Clinical Oncology (ASCO). FCS physicians, trained in prestigious medical schools and research institutes, are consistently ranked nationally as Top Doctors by U.S. News & World Report. Celebrating its 40th year in 2024, FCS has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies genomic-based treatment and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff. *Prior to approval SOURCE Florida Cancer Specialists & Research Institute

FRIDAY, May 19, 2023 -- Adolescent and young adult (AYA) cancer survivors have an increased risk for human papillomavirus (HPV)-associated subsequent malignant neoplasms (SMNs), especially oropharyngeal-SMNs, according to a study published in the May issue of Cancer Epidemiology, Biomarkers & Prevention . Judy Y. Ou, Ph.D., M.P.H., from the Huntsman Cancer Institute at the University of Utah in Salt Lake City, and colleagues identified demographic and clinical risk factors for HPV-associated SMNs (HPV-SMN) among AYA cancer survivors in the Surveillance, Epidemiology, and End Results-9 registries diagnosed from 1976 to 2015. Participants started follow-up two months after their original diagnosis. The researchers found that 1,369 of the 374,408 survivors had an HPV-SMN, which occurred an average of five years after first cancer. AYA survivors had a significantly increased risk for any HPV-SMN and for oropharyngeal-SMNs (standardized incidence ratios [SIR], 1.70 and 2.17, respectively); the risk for cervical-SMN was lower in survivors overall (SIR, 0.85), but was increased in Hispanic AYA survivors (SIR, 1.46). Compared with the general population, AYAs first diagnosed with Kaposi sarcoma, leukemia, and Hodgkin and non-Hodgkin lymphoma had increased risks for HPV-SMN. In age-period-cohort models, oropharyngeal-SMN incidence decreased over time. Among survivors with first HPV-related cancers, but not those whose first cancers were not HPV-related, chemotherapy and radiotherapy were associated with any HPV-SMN. "HPV-SMNs are preventable through screenings and vaccination. Recommending preventative care from diagnosis onwards among AYA survivors is of great importance," the authors write. One author disclosed financial ties to the pharmaceutical industry. Abstract/Full Text (subscription or payment may be required) Posted May 2023